Australasian Journal of Dermatology最新文献

{"title":"Representation of Topical Corticosteroid Withdrawal and Steroid Phobia on TikTok and YouTube Shorts: A Mixed-Methods Content Analysis","authors":"Ju Hee Roh,&nbsp;Terry Kim,&nbsp;Aaron M. Secrest,&nbsp;Harriet Kennedy","doi":"10.1111/ajd.70129","DOIUrl":"10.1111/ajd.70129","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Short-form video platforms such as TikTok and YouTube Shorts have become influential sources of health information. Among dermatology topics, topical steroid withdrawal (TSW) and corticosteroid phobia (‘corticophobia’) are frequently discussed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To examine quantitative engagement patterns and qualitatively characterise representations of TSW and corticosteroid phobia on TikTok and YouTube Shorts.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A qualitative reflexive thematic analysis was conducted on publicly available TikTok and YouTube Shorts videos identified using predefined hashtags. Sampling was restricted to a consecutive two-day period to minimise algorithmic drift. Seventy-six publicly-accessible videos met inclusion criteria. Videos were coded inductively using NVivo, and thematic saturation was assessed through analytic redundancy and code recurrence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>TikTok videos were shorter and more interactive than YouTube Shorts. Sentiment was negative or neutral in most (78.9%, 60/76) videos. Five themes emerged: (1) Visually-dramatic embodiment of TSW; (2) Protest and mistrust; (3) Alternative healing; (4) Identity and hope; (5) Platform-shaped performance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Short-form platforms amplify emotionally intense and distrust-oriented narratives about TSW. Future research should focus on effective strategies to address misinformation and rebuild trust.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"67 5","pages":"e307-e313"},"PeriodicalIF":1.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147728102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of Live and Live-Attenuated Vaccines in Patients Receiving Biologics and Small-Molecule Therapies for Dermatologic Diseases: A Systematic Review","authors":"Alex Li Majri,&nbsp;Jonathan Chan","doi":"10.1111/ajd.70088","DOIUrl":"10.1111/ajd.70088","url":null,"abstract":"<div>\u0000 \u0000 <p>Biologic and small-molecule therapies are increasingly used in dermatology for conditions such as psoriasis and atopic dermatitis. Live and live-attenuated vaccines are traditionally avoided in patients receiving these agents due to concerns regarding vaccine-strain infection. We conducted a systematic review to evaluate the safety of live and live-attenuated vaccines in patients receiving biologic or small-molecule therapies used in dermatologic practice. PubMed, Embase (Ovid) and the Cochrane Library were searched from January 2010 to February 2025 for human studies reporting safety or immunogenicity outcomes following live vaccine administration in patients receiving relevant therapies. Of 1104 records identified, nine studies met inclusion criteria, comprising one randomised controlled trial, three cohort studies, three retrospective case series, one cross-sectional observational study and one case report. Vaccines evaluated included measles-mumps-rubella, measles-mumps-rubella-varicella, varicella, live zoster and yellow fever vaccines. Across studies, no cases of vaccine-strain infection or disseminated vaccine-related disease were reported. Mild and self-limiting post-vaccination reactions were described in several cohorts. Where assessed, immunogenicity responses were generally preserved, although data were limited and inconsistently reported. Most included studies involved patients receiving biologic or small-molecule monotherapy, though some cohorts permitted background conventional immunomodulatory therapy. The available evidence, although limited and predominantly observational, suggests that selected live and live-attenuated vaccines may be administered without serious adverse outcomes in carefully chosen patients receiving biologic or small-molecule therapies. Larger prospective studies are needed to better define safety and immunogenicity across newer targeted agents.</p>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"67 5","pages":"259-269"},"PeriodicalIF":1.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147472738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demographic Analysis of the Sun Protective Behaviours and Skin Cancer Risk of Victorian Farmers","authors":"Eloise Violet Kwan,&nbsp;Jessie Adams,&nbsp;Joanna Macdonald,&nbsp;Susan Brumby,&nbsp;Tracey Hatherell,&nbsp;Feby Savira,&nbsp;Alison Kennedy","doi":"10.1111/ajd.70135","DOIUrl":"10.1111/ajd.70135","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Farmers have an elevated risk of melanoma and non-melanoma skin cancer due to their occupational exposure to high levels of ultraviolet radiation. The sun protective behaviours of farmers are poorly understood, limiting targeted interventions to this at-risk population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aimed to characterise sun protective behaviours among Victorian farmers and to assess whether demographic factors were associated with variations in sun protection uptake.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>A cross-sectional study of 124 Victorian farmers was completed using Health and Lifestyle Assessment data collected by the National Centre for Farmer Health. Associations between sun protective behaviours (sunscreen, sunglasses, long sleeve shirt, long trousers, broad brim hat) and demographic factors (gender, age group, rurality) were investigated with descriptive statistics and ordinal logistic regression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Age group was significantly associated with sunscreen use (<i>p</i> = 0.035). Participants aged 65 years and over were most likely to never use sunscreen, while those aged 50–64 years were most likely to always use it. No significant associations were found between gender or rurality and any sun protective behaviour. Overall, use of sun protection was suboptimal across all demographic groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings suggest that Victorian farmers over 65 years of age may benefit from targeted public health messaging and education from primary care physicians and dermatologists. Further research is required to validate these results given the small sample size. A focus group of at-risk farmers as identified in this study may be valuable to identify interventions that could increase the sun protective behaviours of Australian farmers.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"67 5","pages":"280-287"},"PeriodicalIF":1.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.70135","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147832963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Retrospective Cohort Study of Extended Dupilumab Dosing in Atopic Dermatitis: Assessing the Impact on Disease Severity and Understanding Characteristics Linked to Successful Dose Extension","authors":"Jessica McClatchy,&nbsp;Vanessa Tran,&nbsp;Gayle Ross","doi":"10.1111/ajd.70165","DOIUrl":"10.1111/ajd.70165","url":null,"abstract":"<div>\u0000 \u0000 <p>Dupilumab is effective for moderate-to-severe atopic dermatitis, but optimal long-term dosing is unclear. In this single-centre retrospective study, 49 patients underwent dose extension to 300 mg Q3W or 300 mg Q4W, with EASI scores remaining low and stable over 18 months. Patients extending for good disease control had higher EASI90 rates. The impact of age, disease severity and therapy duration remains uncertain.</p>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"67 5","pages":"e321-e325"},"PeriodicalIF":1.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148293368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic Motion Dermoscopy of Anetodermic Pilomatricoma","authors":"L. T. Fernández,&nbsp;A. Cuellar-Barboza,&nbsp;G. Salerni,&nbsp;J. Ocampo-Candiani,&nbsp;C. M. Harrsch-de la Garza","doi":"10.1111/ajd.70121","DOIUrl":"10.1111/ajd.70121","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"67 5","pages":"e326-e328"},"PeriodicalIF":1.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Embedding Dermatology in a Constrained Curriculum: A Vertically Integrated, Needs-Driven Model Aligned to Junior Doctor Preparedness.","authors":"Matthew J Verheyden, Jessica Bulluss, Chon-Wai Jeremy Chan, Paul Chee","doi":"10.1111/ajd.70190","DOIUrl":"https://doi.org/10.1111/ajd.70190","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148688484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous Adverse Events in Children Receiving Mitogen-Activated Protein Kinase Pathway Inhibitors.","authors":"Yuong Chin Tan, Santosh Valvi, Nicholas G Gottardo, Anne R Halbert","doi":"10.1111/ajd.70191","DOIUrl":"https://doi.org/10.1111/ajd.70191","url":null,"abstract":"<p><strong>Background/objective: </strong>Mitogen-activated protein kinase pathway inhibitors (MAPKi) are increasingly used as targeted therapies for paediatric central nervous system tumours and other malignancies. Cutaneous toxicities, including xerosis, dermatitis, follicular-based infections, acne, and paronychia, are common and may result in significant morbidity and treatment interruption.</p><p><strong>Method: </strong>In this 18-month ambispective observational cohort study, 24 consecutive children receiving MAPKi at a tertiary paediatric centre were included. Patients were followed prospectively, with retrospective data collected for those already receiving therapy at study commencement. The incidence and spectrum of cutaneous adverse events (AE), predisposing factors and management strategies were documented.</p><p><strong>Results: </strong>Overall, 21/24 (87.5%) patients developed at least one cutaneous AE, most commonly xerosis, dermatitis, hair changes, paronychia, and pustular skin infections. Most events were Common Terminology Criteria for Adverse Events (CTCAE) grade 1-2; however, a small number of patients required dose modification or temporary treatment interruption.</p><p><strong>Conclusion: </strong>These findings support early dermatologic assessment and proactive management of MAPKi-associated cutaneous toxicities. We propose practical caregiver-directed skin care recommendations to be introduced at treatment initiation to reduce morbidity and improve treatment tolerability.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148683305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Persistence of Upadacitinib for Atopic Dermatitis: Expanded Analysis From Royal Melbourne Hospital Biogrid Registry and the Australasian Dermatology Registry.","authors":"Nadine Abu-Ghazaleh, Julie Armstrong, Vanessa Morgan, Gayle Ross","doi":"10.1111/ajd.70188","DOIUrl":"https://doi.org/10.1111/ajd.70188","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148676924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prevalence of Adult Atopic Eczema in New Zealand.","authors":"Annabelle Yi Zhang, Dug Yeo Han, Paul Jarrett","doi":"10.1111/ajd.70187","DOIUrl":"https://doi.org/10.1111/ajd.70187","url":null,"abstract":"<p><strong>Introduction: </strong>The prevalence of adolescent and adult atopic eczema (AE) in New Zealand is not known. This study estimates the prevalence and epidemiology in Auckland, New Zealand, from 2017 to 2019, before the COVID-19 pandemic.</p><p><strong>Method: </strong>Every primary health care organisation in Auckland provided diagnostic codes for AE for those aged greater than 15 years. Codes were matched with dispensing records for topical eczema treatments. Active disease was defined as having at least two dispensing events for AE-related treatment within any 12-month period. Data were matched to the National Health Index, which is a unique health identifier assigned to each person receiving health care in New Zealand. Population estimates were derived by linear interpolation from census data for 2013, 2018, and 2023.</p><p><strong>Results: </strong>From 2017 to 2019, the average annual prevalence of AE per 100,000 (95% CI) was 1991 (1968-2015) for all ethnicities, 4625 (4565-4685) for Pacific peoples, 3501 (3440-3561) for Māori and 1296 (1280-1311) for Europeans. Compared to the European population, prevalence rates were higher in Pacific, Māori, and Asian populations (p < 0.001). The most deprived individuals had a higher prevalence per 100,000 population (95% CI) of 3466 (3424-3509) compared with 1737 (1706-1767) in the least deprived, p < 0.001, and the prevalence was highest in the youngest age group, 15-29 years (2766/100,000).</p><p><strong>Conclusion: </strong>There is a higher prevalence of adult AE in Māori, Pacific, and Asian populations compared to the European population, particularly in poorer communities and younger age groups.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148676962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Outcomes and Safety of JAK Inhibitors in Paediatric Alopecia Areata: A Retrospective Multicentre Study.","authors":"Miguel Mansilla-Polo, Aniza Giacaman, Carlos Abril-Pérez, Daniel Martín-Torregrosa, Laura Berbegal-de Gracia, Tania Díaz-Corpas, Ainhoa Fernández-Arregui, Javier Melgosa-Ramos, Alberto Soto-Moreno, Alejandra Ruiz-Villanueva, Juncal Roca-Ginés, Gerard Pitarch-Bort, Altea Esteve-Martínez, Ana Martín-Santiago, Alonso García-Núñez, José Bernabéu-Wittel, María Teresa Monserrat-García, Montserrat Évole-Buselli","doi":"10.1111/ajd.70189","DOIUrl":"https://doi.org/10.1111/ajd.70189","url":null,"abstract":"<p><strong>Introduction: </strong>Alopecia areata (AA) is a non-scarring, immune-mediated hair loss disorder with substantial psychosocial impact in children. Robust paediatric real-world evidence regarding Janus kinase inhibitors (JAKi) for this disease is limited. In this study, we describe real-world clinical outcomes and safety of JAKi for paediatric AA.</p><p><strong>Methods: </strong>We conducted a retrospective, observational multicentre study across 11 Spanish hospitals including patients aged 0-18 years who initiated a first JAKi (baricitinib, tofacitinib, or ritlecitinib) in routine care. The primary outcome was Severity of Alopecia Tool (SALT)-50. Secondary outcomes included the absolute SALT trajectory, eyebrow/eyelash responses, adverse events, and switching to a second JAKi.</p><p><strong>Results: </strong>Forty-six patients were included (baricitinib 22/46 [47.8%], tofacitinib 14/46 [30.4%], ritlecitinib 10/46 [21.7%]; mean age 11.3 ± 4.0 years). Eight patients (21.6%) achieved SALT-50 at weeks 4-8, 21 patients (58.3%) at week 16, 20 patients (80.0%) at week 48, and 14 patients (82.4%) at week 72. Eyebrow and eyelash responses improved concordantly. At week 16, higher baseline SALT reduced the odds of response (β = -0.061, SE 0.029; p = 0.034). Unadjusted response rates varied across drug groups; however, treatment allocation was non-random, and groups were markedly imbalanced at baseline, so drug-level comparisons are exploratory and likely confounded by indication. Response was lower in universalis (unadjusted p = 0.008). Adverse events occurred in 16 of 46 patients (34.8%), mostly mild, with two patients (4.3%) discontinuing treatment. A second JAKi was used in seven patients (15.2%): Three complete, two partial, and two absent responses occurred post-switch.</p><p><strong>Discussion: </strong>In real-world paediatric practice, we observed improvements in scalp, eyebrow, and eyelash involvement with JAKi use, with a generally favourable tolerability profile. Given the observational design, baseline imbalances, and missing data, causal inference and between-drug comparisons are not supported.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148673014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}